Structural Correction
Structural correction should name the deficit and the expected time course. Focal depression, wrinkle or fold correction, contour support, and broader volume restoration are related but not interchangeable objectives.
Define the structural problem
Section titled “Define the structural problem”Record:
- exact anatomical feature and side
- whether the issue is focal, linear, regional, or diffuse
- the baseline contribution of bone, ligament, fat, muscle, and skin
- whether immediate physical correction is required
- whether staged, delayed change is acceptable
- how improvement will be measured without relying on memory
“Lift” is not sufficiently specific unless it is tied to an observable contour relationship or validated assessment.
Product systems create different structural phases
Section titled “Product systems create different structural phases”| Product system | Immediate appearance | Later interpretation |
|---|---|---|
| Reconstituted PLLA or PDLLA suspension | Injected fluid and edema may temporarily occupy space | Later change must be assessed after the early fluid phase resolves |
| PDLLA + HA hybrid | Prepared fluid, HA, edema, and particles can all contribute | HA-related and particle-related phases should remain separate |
| CaHA microspheres in CMC carrier | Carrier provides immediate physical correction in structural use | Carrier change and microsphere-associated tissue response alter the later result |
| PCL microspheres in carrier gel | Carrier contributes immediate structure | Later correction should not be attributed entirely to persistent carrier or entirely to collagen |
Radiesse and Ellansé are documented carrier-and-particle examples. Sculptra and AestheFill illustrate why early prepared-fluid fullness is not the final response.
Immediate structure is not one property
Section titled “Immediate structure is not one property”The relevant questions include:
- Is the early correction produced by a structural gel carrier, HA, or reconstitution fluid?
- Does the exact presentation retain focal structural behavior after any permitted preparation?
- Is the objective within the current local intended use?
- Does the supporting study measure contour, wrinkle severity, volume, or only a global improvement score?
- At what time was the reported correction assessed?
Sinclair describes Ellansé’s CMC-containing carrier as providing immediate structural correction, followed by a later collagen-related phase (Sinclair Ellansé 🔗). Merz describes Radiesse as CaHA particles in a CMC gel with immediate lift and contour language, but exact indications and preparation remain variant-specific (Radiesse professional information 🔗).
Dilution can change the objective
Section titled “Dilution can change the objective”A preparation discussed for broad distribution or skin attributes should not be assumed to retain the same focal structural behavior as the supplied implant.
The March 31, 2026 US Radiesse approval provides one regulated example: 1:2 dilution with sterile saline for subdermal correction of décolleté wrinkles in patients 22 years and older (FDA P050052/S162 🔗). It is not a universal authorization for diluted CaHA or a conversion rule for other areas.
Evidence fit
Section titled “Evidence fit”Prefer evidence that measures the actual structural objective:
| Objective | More compatible outcome |
|---|---|
| Fold or wrinkle correction | Validated severity scale with standardized photography |
| Contour support | Reproducible profile or three-dimensional assessment |
| Volume restoration | Standardized volumetric or anatomical assessment |
| Global appearance | GAIS can supplement, but not replace, objective-specific measures |
Patient satisfaction matters, but it does not establish the mechanism or amount of structural correction.
Decision output
Section titled “Decision output”Before product selection, the record should state:
- defined structural deficit
- required immediate and delayed phases
- exact candidate product and presentation
- compatible evidence and its anatomical scope
- local approved or off-label status
- baseline and reassessment method
Continue to immediate vs delayed effects for outcome attribution.